This bill mandates that health benefits plans and contracts for hospital and medical expense benefits, as well as Medicaid, provide coverage for a 12-month refill of prescription hormone replacement therapy, provided that the therapy does not require refrigeration. The definition of prescription hormone replacement therapy includes all FDA-approved drugs used to medically suppress, increase, or replace hormones that the body is not producing at intended levels, with the exception of glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists. Additionally, if the therapy is classified as a controlled dangerous substance, the maximum refill allowed under state and federal law must be provided.
The bill also allows for certain limitations on refills, such as restricting them in the last quarter of the plan year if a 12-month supply has already been dispensed, and permitting prescribing providers to temporarily limit refills to a 90-day supply during acute dispensing shortages. Furthermore, health benefits plans may apply drug utilization management strategies to the covered prescription drugs, as long as they are not otherwise prohibited by the bill or existing laws. The act is set to take effect immediately and will apply to health benefits plans and contracts issued or renewed after its enactment.